Next 10 |
home / stock / mdxg / mdxg articles
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securit...
MARIETTA, Ga., Jan. 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it has enhanc...
NEW YORK, Jan. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential se...
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the...
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday. Shares of Rivian Automotive, Inc. (NASDAQ: RIVN) f...
MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of it...
MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced it will sponsor an...
U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today&rsquo...
MARIETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will repor...
News, Short Squeeze, Breakout and More Instantly...
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 3...
Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Doubl...
MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity ...